The Valiant Efforts of Dr. Clay Siegall in Cancer Research

Fighting cancer is no east task. Hours and hours of research goes into each and every medication as well as copious amounts of testing. These advanced medications has to pass a series of tests before they can ever hit the market. In most cases, a newly developed drug can take years before it gets an FDA-approval. Rome wasn’t built in a day and effectively fighting cancer takes more than one day to see results. Dr. Clay Siegall of Seattle Genetics knows this, and he doesn’t mind putting in the hard work. Dr. Siegall is very important to cancer research thanks to his experience, his expertise and his passion. He is the very definition of a civil servant.

Dr. Siegall began his medical career with Bristol Myers Squibb, but as of today, he is the CEO for one of the world’s top cancer-research organizations. Transformative-cancer therapy is the name of the game and Seattle Genetics produces some of the best drugs. As of 2018, the company has earned more than $350 million from its premier drug ADCETRIS. This power medication has been on the market since 2011. By securing multiple-strategic licensing, this medication can be used in up to 60 different countries. That’s right! Dr. Siegall has secured deals with some of the top pharmaceutical companies in the world like Bayer, GlaxoSmithKlien and Genentech. In just five short years, the company’s stock prices has nearly tripled.

Dr. Siegall is also one of the most accomplished individuals in the business thanks to his multiple degree, and his high number of patents. This guy has literally written up to 70 publications that pertains to the subject. In conclusion, Dr. Clay Siegall has reached the pinnacle of cancer research, and he’ll continue to display excellence while changing the status quo.